Nancy Y. Lee, MD, FASTRO is a radiation oncologist who holds the positions of vice president of Department of Radiation Oncology, and service chief, for Head & Neck Radiation Oncology and Proton Therapy at Memorial Sloan Kettering Cancer Center.
The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.
Published: May 6th 2021 | Updated: